Neurodegenerative diseases are plenty in number, but to find the ultimate research is still ongoing worldwide. One company involved in this process is Suven Life Sciences. They have discovered novel chemical entities responsible for the treatment of neurodegenerative diseases, which were claimed for patenting.

On 7^th August 2018, Suven Life Sciences successfully secured one patent each from New Zealand and Mexico and which will remain valid through 2030 and 2036 respectively. Hence the market shares of Suven Life Sciences rose by 1.6 percent on the same day.

The patents were granted for the discovery of a class of selective H3 and 5-HT4 compounds respectively which are being developed as successful therapeutic agents for neurodegenerative disorders like cognitive impairment associated with varied neurodegenerative diseases which include attention deficient hyperactivity disorder (ADHD), Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, schizophrenia and sleep disorders like narcolepsy, sleepwalking, night terrors, insomnia and obstructive sleep apnoea.

Venkat Jasti, CEO of Suven Life Sciences said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."